Cancer and its treatment are often associated with symptoms such as depression, somnolence, cognitive abnormalities, and fatigue. Methylphenidate, a stimulant medication, is commonly used to treat these symptoms. Several small pilot and a few adequately powered studies have assessed the safety and efficacy of methylphenidate in patients with cancer. Overall, the studies so far suggest that methylphenidate is well-tolerated in patients with cancer. Further, the studies have provided initial evidence of efficacy of this agent in patients with cancer. The present article reviews the evidence base behind the use of methylphenidate in these patients.
Wilens TE: Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs. 2003; 63(22): 2395-2411.
2.
Challman TD, Lipsky JJ: Methylphenidate: Its pharmacology and uses. Mayo Clin Proc. 2000; 75(7): 711-721.
3.
Hurd YL, Ungerstedt U: In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol. 1989; 166(2): 251-260.
4.
Volkow ND, Wang GJ, Fowler JS, et al.: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998; 155(10): 1325-1331.
5.
Volkow ND, Ding YS, Fowler JS, et al.: Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995; 52(6): 456-463.
6.
Ferris RM, Tang FL: Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of l-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum, and hypothalamus. J Pharmacol Exp Ther. 1979; 210(3): 422-428.
7.
Gatley SJ, Pan D, Chen R, et al.: Affinities of methylphenidate derivatives for dopamine, norepinephrine, and serotonin transporters. Life Sci. 1996; 58(12): 231-239.
8.
Patrick KS, Caldwell RW, Ferris RM, et al.: Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther. 1987; 241(1): 152-158.
9.
Srinivas NR, Hubbard JW, Quinn D, et al.: Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther. 1992; 52(5): 561-568.
10.
Dexmethylphenidate—Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride. Drugs R D. 2002; 3(4): 279-282.
11.
Masand PS, Tesar GE: Use of stimulants in the medically ill. Psychiatr Clin North Am. 1996; 19(3): 515-547.
12.
Gawin FH, Ellinwood EH Jr: Cocaine and other stimulants. Actions, abuse, and treatment. N Engl J Med. 1988; 318(18): 1173-1182.
13.
Fernandez F, Adams F, Holmes VF, et al.: Methylphenidate for depressive disorders in cancer patients. Psychosomatics. 1987; 28(9): 455-461.
14.
Nathenson AL: Clinical evaluation of Ritalin. Dis Nerv Syst. 1956; 17: 392-396.
15.
Holmes VF, Fernandez F, Levy JK: Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry.. 1989; 50(1): 5-8.
16.
Wilens TE, Faraone SV, Biederman J, et al.: Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003; 111(1): 179-185.
17.
Parran TV Jr, Jasinski DR: Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med. 1991; 151(4): 781-783.
18.
Jaffe SL: Failed attempts at intranasal abuse of Concerta. J Am Acad Child Adolesc Psychiatry. 2002; 41(1): 5.
19.
Homsi J, Nelson KA, Sarhill N, et al.: A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001; 18(6): 403-407.
Olin J, Masand P: Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996; 37(1): 57-62.
22.
Fernandez F, Adams F: Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg. 1986; 8(4): 296-300.
23.
Homsi J, Walsh D, Nelson KA, et al.: Methylphenidate for depression in hospice practice: A case series. Am J Hosp Palliat Care. 2000; 17(6): 393-398.
24.
Lavretsky H, Kim MD, Kumar A, et al.: Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: An open trial. J Clin Psychiatry. 2003; 64(12): 1410-1414.
25.
Rothenhausler HB, Ehrentraut S, von Degenfeld G, et al.: Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. J Clin Psychiatry. 2000; 61(10): 750-755.
26.
Grade C, Redford B, Chrostowski J, et al.: Methylphenidate in early poststroke recovery: A double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998; 79(9): 1047-1050.
27.
Bruera E, Fainsinger R, MacEachern T, et al.: The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992; 50(1): 75-77.
28.
Bruera E, Brenneis C, Paterson AH, et al.: Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 1989; 4(1): 3-6.
29.
Yee JD, Berde CB: Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage. 1994; 9(2): 122-125.
30.
Bruera E, Chadwick S, Brenneis C, et al.: Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987; 71(1): 67-70.
31.
Bruera E, Miller MJ, Macmillan K, et al.: Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992; 48(2): 163-166.
32.
Wilwerding MB, Loprinzi CL, Mailliard JA, et al.: A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995; 3(2): 135-138.
33.
Meyers CA, Weitzner MA, Valentine AD, et al.: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998; 16(7): 2522-2527.
34.
DeLong R, Friedman H, Friedman N, et al.: Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. J Child Neurol. 1992; 7(4): 462-463.
35.
Gagnon B, Low G, Schreier G: Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: A prospective clinical study. J Psychiatry Neurosci. 2005; 30(2): 100-107.
36.
Weitzner MA, Meyers CA, Valentine AD: Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci. 1995; 7(3): 347-350.
37.
Mulhern RK, Khan RB, Kaplan S, et al.: Short-term efficacy of methylphenidate: A randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol. 2004; 22(23): 4795-4803.
38.
Thompson SJ, Leigh L, Christensen R, et al.: Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001; 19(6): 1802-1808.
39.
Sood A, Moynihan TJ: Cancer-related fatigue: An update. Curr Oncol Rep. 2005; 7(4): 277-282.
40.
Bruera E, Driver L, Barnes EA, et al.: Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol. 2003; 21(23): 4439-4443.
41.
Schwartz AL, Thompson JA, Masood N: Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate. Oncol Nurs Forum. 2002; 29(7), Online Exclusive: E85-E90.
42.
Sarhill N, Walsh D, Nelson KA, et al.: Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study. Am J Hosp Palliat Care. 2001; 18(3): 187-192.
43.
Breitbart W, Rosenfeld B, Kaim M, et al.: A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med. 2001; 161(3): 411-420.
44.
Rammohan KW, Rosenberg JH, Lynn DJ, et al.: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002; 72(2): 179-183.
45.
Bruera E, Driver L, et al.: Patient-controlled methylphenidate (PCM) for cancer-related fatigue (CRF): A randomized controlled trial. Paper presented at 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13-17, 2005.
46.
Lower E, Fleishman S, Cooper A, et al.: A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as a new treatment of fatigue and “chemobrain” in adult cancer patients. Paper presented at 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13-17, 2005.
47.
Rozans M, Dreisbach A, Lertora JJ, et al.: Palliative uses of methylphenidate in patients with cancer: A review. J Clin Oncol. 2002; 20(1): 335-339.
